Chinese drug makers downplay US threat
Chinese pharmaceutical executives sought to reassure investors after a report said the US may restrict licensing deals for China-developed drugs. Shares of Hong Kong-listed firms fell, but at BioHK 2025, leaders from Grand Pharma, China Resources Pharma, CureGene, and Yunnan Baiyao said risks could be managed through diversification, regionalization, and overseas clinical trials.